Light Mode
$19.12 ↑ +0.23 (+1.22%) Trading Up from the previous close of $18.89, $0.27 below the day’s high of $19.39
-12.10 (-39.04%) / 6M
Momentum, market sentiment, and recent alerts
NAMS reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -49.0%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.